A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518015-19-00

Acronym

M24-534

Enrollment

Registered

2025-07-29

Start date

2025-09-24

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Percentage of Participants with disease free survival (DFS) Event

Detailed description

Change in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Clearance at 6 months, Overall Survival (OS)

Interventions

DRUGTelisotuzumab adizutecan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with disease free survival (DFS) Event	—

Secondary

Measure	Time frame
Change in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Clearance at 6 months, Overall Survival (OS)	—

Countries

Belgium, Denmark, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026